Industry seeks clarity on FDA’s standards recognition process for regenerative medicines

Commenters on a recent draft guidance released by the US Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER) support the idea of creating a voluntary consensus standards (VCS) recognition program for regenerative medicine therapies (RMTs) but want more details from the agency on the types of VCS recognized and the process for engaging FDA through the program.